Liver Function and Inavolisib Study
Treatments studied
Part of Digestive system clinical trials.
This study tests how the body processes the drug inavolisib when taken by people with moderate or severe liver problems compared to those with healthy livers. It helps doctors understand the right dose for patients with liver impairment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with a body mass index (BMI) between 18 and 40, and weigh at least 99 pounds (45 kg).
- You cannot have certain active infections like hepatitis B, hepatitis C, HIV, or tuberculosis.
- If you are a woman, you must be past menopause or have had surgery to prevent pregnancy, and not be breastfeeding.
- If you are a man, you must agree to use birth control and not donate sperm during the study.
- Your liver function must be either normal (for the healthy group) or be in the moderate-to-severe range (for the liver impairment group) with stable cirrhosis.
- You cannot have diabetes that needs insulin or two or more pills, or a history of certain serious illnesses or recent major surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests how two investigational medicines move through the body and how safe they are in people with different levels of liver impairment, compared with healthy volunteers. It may help doctors understand dosing and safety for people with liver problems.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This study tests how a new medicine, BI 3000202, is absorbed into the blood. It includes people with different levels of liver function (normal, mild, moderate, or severe) to see if liver problems affect how the medicine works.
This research study tests how two experimental drugs (AZD9550 and AZD6234) work in people with different levels of liver function. The goal is to understand whether liver disease changes how the body processes these medications, which may help doctors safely treat patients with liver problems in the future.
This trial tests how the drug capivasertib is processed by the body and how safe it is in people with moderate liver impairment. It aims to find the right dose for patients whose liver function is reduced but stable.
This trial tests whether a new targeted pill (inavolisib) plus hormone therapy (fulvestrant) can slow or stop breast cancer growth in people whose cancer has a specific genetic change called a PIK3CA mutation. It is for patients whose disease worsened after previous hormone-and-CDK-inhibitor treatment.
Hear when a new Hepatic Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.